

ROBERT R. CONLEY, MD

Distinguished Lilly Scholar
Eli Lilly and Company
Indianapolis, Indiana

Adjunct Professor of Psychiatry,
Affiliate Professor of Pharmacy Practice and Science,
University of Maryland, Baltimore

Robert Conley is the Chief Science Officer for the Lilly Biomedicine Neuroscience program. This group is responsible for the development of novel non-opioid pain therapies, novel treatments for dementia, and other neurology indications. He is also responsible for coordinating new entries into Phase II and III at Lilly from both Lilly Research Labs and outside developmental partnerships.

He was the leader of the Migraine and Related Therapeutics Development from 2013-18. The group was responsible for the development of novel non-opioid pain therapies, such as anti-CRGP and Lasmiditan. During his tenure, Emgality (galcanezumab) was approved for migraine prevention in the US and EU; galcanezumab was found to be effective for the treatment of cluster headache and submitted to the FDA with Breakthrough Therapy status; and lasmiditan was submitted for the treatment of acute migraine to the FDA.

Dr. Conley led the Late Phase Regulatory Science Group in Biomedicines for Eli Lilly from 2010-13. This group is responsible for development and approval of medications in autoimmune disorders, bone/muscle/joint disorders, cardiology, general medicine, hormonal therapy, neurology, pain, and psychiatry.

He is an Adjunct Professor of Psychiatry and Affiliate Professor of Pharmacy Practice and Science at the University of Maryland. His research interests are in developing better treatments for people with psychosis; the basic neuroanatomy and physiology of the brain related to serious mental disorders; and bioethics.

Dr. Conley received a BA with honors from the Johns Hopkins University and an MD with honors from the University of Maryland School of Medicine. He was the Chief Resident at the Western Psychiatric Institute and Clinic at the University of Pittsburgh. He is board certified by the American Board of Psychiatry and Neurology.

He has received the Laughlin Award for Merit from the National Psychiatric Endowment Fund Fellowship; the Young Investigator Award from the International Congress on Schizophrenia Research; several Teacher of the Year Awards from the Department of Psychiatry at the University of Maryland, Baltimore; and an Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. He is listed in *Who's Who in America* and *Who's Who in Science & Engineering*. He has co-authored more than 300 journal articles, 15 book chapters, and the *Pharmacological Treatment of Schizophrenia*, now in its third edition.

He is a member of a number of professional societies, including the American Association for the Advancement of Science, the Society for Neuroscience, the Society of Biological Psychiatry, and is a Fellow of the American College of Neuropsychopharmacology.